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ABBREVIATIONS 
ABPM = ambulatory blood pressure monitoring 
BMI = body mass index 
CT90 = cumulative time percentage of saturation <90% 
DBP = diastolic blood pressure 
EDS = excessive daytime sleepiness 
ODI = oxygen desaturation index 
OSA= obstructive sleep apnea 
RDI = respiratory disturbance index 
SBP = systolic blood pressure 
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ABSTRACT  
Background: Evidence from longitudinal studies has reported contradictory 
results regarding the association between obstructive sleep apnea (OSA) and 
hypertension. In a previous analysis of the Vitoria Sleep Cohort, we evaluated 
the relationship between OSA and the risk of developing hypertension and we 
did not find an independent association after adjustment for confounding 
factors. In the present study, we perform a post hoc analysis to assess the 
association between OSA and incident stage 2 hypertension (systolic blood 
pressure ≥ 160 mmHg and/or diastolic blood pressure ≥ 100 mmHg) based on 
gender differences. 
Methods: A prospective study was performed over 7.5 ± 0.8 years on a middle-
aged general population, which included 1,155 normotensive subjects (43.7% 
men) who completed the follow-up. Blood pressure measurements (at baseline 
and follow up) and polygraphy at baseline were performed. Logistic regression 
models were used to determine the association between the respiratory 
disturbance index (RDI) and stage 2 hypertension and a recursive partitioning 
method was used to determine the variables related to the incidence of stage 2 
hypertension. The RDI was divided into subgroups (0-2.9, 3-6.9, 7-13.9 and 
≥14), using the first subgroup as reference.  
Results: For men, an RDI ≥ 14 was associated with a significantly increased 
odds ratio (OR) for stage 2 hypertension [OR = 2.54 (95% CI 1.09-5.95), p = 
0.032]. This association was not statistically significant among women (p = 
0.371).  
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Conclusions: Our results suggest an association between moderate to severe 
OSA and the incidence of more severe forms of hypertension in men but not in 
women. However, as this is a community-based study, our women’s population 
characteristics may differ from women usually seen in sleep-disorders clinics. 
 
 
Number of words: 273. 
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INTRODUCTION  
 Evidence from several cross-sectional studies 1-3 suggests an association 
between obstructive sleep apnea (OSA) and hypertension. However, conflicting 
results have emerged from prospective studies 4-7 and currently, the 
pathophysiological interactions between OSA and hypertension are not 
completely understood. Evidence of an association between OSA and 
hypertension is also indicated by several intervention trials, in which CPAP was 
shown to reduce blood pressure 8-10 or in which CPAP withdrawal resulted in a 
clinically relevant increase in blood pressure. 11 However, this improvement in 
blood pressure control is not equally observed in all OSA patients on CPAP 
treatment, suggesting the occurrence of different OSA subgroups. Studies 
performed on subjects without daytime sleepiness have failed to show a 
significant effect of CPAP on blood pressure, 12, 13 other studies reported only a 
minor blood pressure reduction in normotensive subjects, 14, 15 a modest 
reduction in hypertensive patients, 16 or no significant effect in resistant 
hypertension, 17 whereas others have shown a significant blood pressure 
reduction in patients with severe or refractory hypertension. 18, 19  
We evaluated in a previous analysis of the Vitoria Sleep Cohort the 
relationship between OSA and the risk of developing hypertension and our 
findings did not suggest an independent association between OSA and the 
incidence of hypertension, and revealed no sex differences.6
 
In the present 
study we performed a post hoc analysis to assess the relationship between 
OSA and the risk of developing moderate to severe hypertension, which 
corresponds to grade 2 and 3 in the European Task Force for the management 
of arterial hypertension 20 and to stage 2 in the American guidelines. 21 This 
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stage has at least a moderate 10-year risk of cardiovascular mortality and, for 
this reason, current guidelines recommend treating these patients with 
antihypertensive treatment regardless of the presence of other cardiovascular 
risk factors. 20 Recent guidelines have also underlined the paucity of data for 
treating grade 1 hypertension, 22 recommending treatment only after confirming 
hypertension by ABPM and restricting treatment to grade 1 hypertensive 
patients with signs of organ damage or at high total cardiovascular risk.  
 
METHODS 
Study design and patients 
Details of the study design have been previously published. 6, 23 Briefly, it 
is a prospective study performed over 7.5 ± 0.8 years on the middle-aged (30-
70 years) general population of the Vitoria Sleep Cohort to assess the 
association between OSA and hypertension. This cohort enrolled a group of 
1,521 subjects who met the inclusion criteria for the cross-sectional baseline 
study 23 and underwent a structured interview that included sleep 
questionnaires, a physical examination with anthropometric and blood pressure 
measurements and a nocturnal polygraphy. At the end of the monitoring period, 
blood pressure was measured again. The exclusion criteria for the present 
study included subjects treated with CPAP or uvulopalatopharyngoplasty and 
subjects who had hypertension at baseline. The main objective of the present 
study was to assess the association between OSA and the risk of developing 
more clinically significant hypertension (i.e. moderate to severe hypertension) 
and to evaluate sex differences. 
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The study was approved by the OSI Araba Hospital Ethics Committee 
(approval no. 2010-027) and written informed consent was obtained from all 
patients.  
Study variables 
An unattended at-home polygraphy (MESAM IV; Medizintechnik für Artz 
und Patient, Munich, Germany) 24 was performed for all participants to classify 
the population according to the respiratory disturbance index (RDI). In our 
analyses, the RDI was divided into subgroups (0-2.9, 3-6.9, 7-13.9 and ≥14/h), 
using the first subgroup as reference.  
Blood pressure was measured at the beginning and at the end of the 
study with a mercury sphygmomanometer following standard recommendations 
25
.Hypertension was defined as systolic blood pressure (SBP) ≥ 140 mmHg 
and/or diastolic blood pressure (DBP) ≥ 90 mmHg or current treatment with 
antihypertensive medications and it was classified in three grades following 
standard guidelines: 20 grade 1 included all subjects with SBP = 140-159 mmHg 
and/or DBP = 90-99 mmHg; grade 2 included subjects with SBP = 160-179 
mmHg and/or DBP = 100-109 mmHg; and grade 3 included subjects with SBP ≥ 
180 mmHg and/or DBP ≥ 110 mmHg. For our study, we classified our patients 
in two stages: stage 1 corresponded to mild hypertension and included all 
subjects with grade 1 hypertension and stage 2 corresponded to moderate-to-
severe hypertension and included all subjects with grade 2 or 3 hypertension or 
those on current treatment with antihypertensive medications. 
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 Excessive daytime sleepiness (EDS) was defined as sleepiness 
occurring at least 3 or more days a week during the past 3 months under one or 
more of the following conditions: after waking, during free time (leisure time), at 
work or driving, or during daytime in general according to the Basic Nordic 
Sleep Questionnaire. 26 
Statistical analysis  
 Univariate associations with hypertension after follow up were assessed 
using the Mann-Whitney U test for continuous variables and Fisher's exact test 
for categorical variables. Logistic regression models were used to determine the 
association between RDI and stage 2 hypertension incidence. Age, sex, body 
mass index (BMI) and neck circumference were included in the adjusted models 
because they were significantly associated based on the univariate analysis (e-
Table 1). A recursive partitioning method (AnswerTree Software for SPSS Inc., 
Chicago, IL, USA) was used to determine the variables that were related to 
stage 2 hypertension incidence. The tree-building process involved the 
variables: age, sex, BMI, neck circumference and RDI. Recursive partitioning 
identified the threshold value for each variable that provided the best separation 
for identifying stage 2 hypertension with the highest purity, except for the BMI 
variable, which was previously categorized in two groups: BMI < 30 Kg/m2 and 
BMI ≥ 30 Kg/m2. The variable that achieved the most precise separation of 
patients with and without stage 2 hypertension was selected as the best 
predictor for the first branch of the tree. The recursive partitioning procedure 
was repeated for the two subgroups resulting from each split until reaching a 
subgroup that contained fewer than 25 patients or was more than three levels 
deep. Logistic regression analyses were used to estimate the odds ratios for 
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stage 2 hypertension within each subgroup defined according to the previous 
tree and in reference to the subgroup with the lowest prevalence of stage 2 
hypertension. All statistical analyses were performed using IBM SPSS version 
23.0 (SPSS Inc., Chicago, IL, USA) or R, 27 with a significance level of 0.05. 
 
RESULTS 
The flow chart of the patients included in the study is depicted in Figure 1 
and the main characteristics of the normotensive patients at baseline are 
presented in Table 1. These subjects were middle-aged and normoweight on 
average. Almost one-fifth of the population had excessive daytime sleepiness 
and a high percentage of participants reported smoking and alcohol 
consumption. Greater than two-thirds of the female participants were 
premenopausal according to their average age. The presence of moderate to 
severe sleep apnea was higher in men than in women and men showed a 
higher cumulative time percentage of SaO2 <90% (CT90) than women. After 
7.5 ± 0.8 years of follow up (Table 2), the incidence of hypertension in the 
general sample was 33%, and 90 (23%) of these patients developed stage 2 
hypertension. In addition, a statistically significant difference in the stage 2 
hypertension incidence was observed between men and women (13.7% and 
3.2%, respectively (p < 0.001)). Almost three-quarters (72%) of the subjects 
who developed stage 2 hypertension were on antihypertensive medication, 
being this percentage higher in women than in men (86% vs. 68% respectively, 
p<0.001). 
The relationship between the baseline RDI and final hypertension stage 
for normotensive patients at baseline is presented in Figure 2. Differences were 
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not observed in the baseline RDI between the subjects who developed stage 1 
hypertension and the subjects who remained normotensive (median RDI of 4/h). 
However, a significant difference was observed in the baseline RDI between 
both groups and the group that developed stage 2 hypertension (median RDI of 
8/h and Bonferroni adjusted p-value < 0.0001 for both comparisons).   
The association between the baseline RDI and the incidence of stage 2 
hypertension is presented in Table 3. The OR significantly increased with higher 
RDI categories and after controlling for age, sex, BMI and neck circumference 
[at RDI ≥14, OR = 2.51 (95% CI 1.18-5.33), overall p trend = 0.017].  
We also examined the association between the baseline RDI and the risk 
of developing stage 2 hypertension stratified by sex (Table 4) because of the 
significant interactions of sex with neck circumference (p = 0.047) and age (p = 
0.028), and we controlled for the same variables except for sex. In the case of 
men, a baseline RDI ≥14 was associated with a significantly increased OR for 
the development of stage 2 hypertension [OR = 2.54 (95% CI 1.09-5.95), 
overall p trend = 0.032]. This association was not statistically significant among 
women (overall p trend = 0.371), although the OR for women increased with 
higher RDI categories. 
The relationship between the RDI categories and the incidence of 
hypertension was also evaluated considering the presence or absence of EDS. 
The OR did not significantly increase with higher RDI categories in subjects with 
EDS (crude OR, p = 0.228) or in subjects without EDS (crude OR, p = 0.102). 
These results were also confirmed by the absence of statistical significance in 
the interaction between the RDI and sleepiness (p value for interaction = 0.653). 
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A decision tree of risk factors for incident stage 2 hypertension was 
constructed according to the recursive partitioning method and is presented in 
Figure 3, and the probability of developing stage 2 hypertension in each 
subgroup is shown in Table 5. Seven risk subgroups were noted based on the 
following risk variables (which had their own threshold values): age, sex, BMI, 
neck circumference and RDI. We estimated the odds ratios of presenting stage 
2 hypertension using the subgroup with the lowest Stage 2 hypertension 
incidence (non-obese and ≤ 56 years women) as reference. An RDI ≥14/h was 
the main risk factor for hypertension incidence in men but not in women [OR in 
men = 25.33 (95% CI 9.76-65.73) p < 0.001, with an incidence of 22.6% of 
Stage 2 hypertension]. In the case of women, OSA presence was not a 
significant risk factor for stage 2 hypertension development. The majority of 
women in our sample (81%) belonged to the lowest risk subgroup for stage 2 
hypertension incidence (young and non-obese women), although there was a 
subgroup of women (3.8%) (older than 56 years with a neck circumference 
diameter > 35.3 cm) who had the highest Stage 2 hypertension incidence of our 
sample (28.0%) [OR = 33.70 (95% CI 10.28-110.50), p < 0.001], regardless of 
their RDI. 
 
DISCUSSION 
Our post hoc analysis suggest an association between moderate to 
severe OSA and the risk of developing more severe forms of hypertension in 
middle-aged men of the general population after 7.5 years of follow up. Men 
with a RDI ≥ 14/h exhibited a 2.5-fold increased risk of developing stage 2 
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hypertension compared with those without OSA. In women, this relationship 
was not statistically significant. An analysis of the risk subgroups for stage 2 
hypertension incidence confirmed this gender difference and showed that 
moderate to severe OSA was the main risk factor for hypertension development 
in men. EDS did not appear to modify this relationship. 
As our previous findings did not support a causal relationship between 
OSA and hypertension in the middle-aged general population, we performed 
this post hoc analysis to evaluate the association between OSA and the risk of 
developing more clinically significant hypertension (i.e. stage 2 hypertension), 
due to the cardiovascular consequences of this stage of hypertension and the 
potential benefit of treating OSA patients to prevent them. Among the three 
prospective studies that have assessed the association between OSA and 
hypertension 4,5,7, two of them 5,7 did not analyze the different stages of 
hypertension, while the Wisconsin Sleep Cohort Study 4 evaluated the 
prevalence of stage 1 and 2 of hypertension but did not determinate the 
incidence of both stages of hypertension because they could not precisely 
identify the participants normotensive at baseline. 
To the best of our knowledge, this is the first attempt to explore different 
clinical OSA subgroups related to hypertension incidence using the recursive 
partitioning method. Our objective was to explore all risk factors for developing 
stage 2 hypertension to identify clinical subgroups and provide insights into the 
association between OSA and hypertension. In addition to the RDI, we found 
that age was a clinically and statistically significant risk factor for both genders 
(although the cut-off point was different), and neck circumference and BMI were 
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clinical variables that identified different risk subgroups only in women. In recent 
years, several studies have attempted to identify different OSA subgroups using 
a different statistical approach: the cluster analysis. Ye and co-workers 28 
identified three distinct clusters and demonstrated an increased probability of 
hypertension in minimally symptomatic patients compared with those with EDS. 
In a recent paper, Lacedonia et al. 29 also identified three different subgroups of 
OSA patients, being those who belonged to the cluster with higher apnea-
hypopnea index and higher nocturnal hypoxemia, who presented the highest 
prevalence of hypertension. In our study, neither symptoms (EDS) nor nocturnal 
hypoxia, which were assessed by CT90 and the oxygen desaturation index 
(ODI), were independently associated with incident hypertension. 
The slight association between OSA and stage 2 hypertension observed 
in women in our study could be related to several factors: mainly, the small 
number of women with an RDI ≥ 14/h and with stage 2 hypertension in our 
sample; the high proportion of premenopausal (67.4%) and consequently young 
women (44.4 ± 9.6 years), a status with lower prevalence of OSA and 
hypertension; 30  the lower BMI for women compared with men (24.1 ± 3.7 
Kg/m2 vs. 26.0 ±3.0 Kg/m2 respectively, p< 0.001); and, finally,  the lower 
prevalence of OSA and hypertension in women than in men. 31,32  All these 
factors could suggest a possible increased level of cardiovascular protection 
and/or a longer required exposure time for the expression of hypertension in 
women than in men. Our data are consistent with a case-controlled study 
performed by Hedner et al., 33 who found an independent association between 
OSA and hypertension with a dose-response effect in men but not in women 
and with the results from the cross-sectional study of the Yale Sleep Cohort 
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Study, 34 although gender differences were observed only in the highest BMI 
quartile. Our results differ from a recent large database study 35 and the SHHS 
results, 5 which suggested that OSA might predict future hypertension among 
women but not men. Other population-based studies have not revealed an 
association with gender. 1, 4, 36  
Regarding to daytime sleepiness, conflicting results have emerged. 28, 37 
In our study, EDS did not appear to modify this relationship. Consistent with our 
results, Marin and co-workers 7 did not find an association between the Epworth 
Sleepiness Scale score and the incidence of hypertension in OSA patients who 
were not treated with CPAP. The discrepancies observed between our study 
and other studies could be related to the sample population (general population 
vs. sleep-disorder clinics) or the different methods used to assess sleepiness 
(we used the Basic Nordic Sleep Questionnaire, which is a questionnaire that 
has been widely used and shown to be a valid tool for epidemiological and 
genetic research for OSA).38 
Our study presented a number of potential limitations. We used office 
blood pressure measurements instead of 24-hour ABPM. However, the use of 
office blood pressure measurements has been validated in several studies and 
is recommended as the screening method for hypertension assessments, 21 
whereas ABPM is costly and time consuming when performed on a large 
population. nother potential limitation is that polysomnography was not 
performed on all subjects. However, the data obtained for participants who 
underwent both polygraphy and polysomnography did not show any significant 
differences in the association between OSA and hypertension.23 Finally, the 
majority of our general population had mild to moderate sleep apnea; therefore, 
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patients with severe OSA were not well represented. This is especially relevant 
in the case of women, were the small number of women with a RDI ≥ 14/h and 
with stage 2 hypertension incidence, may reflect low study power rather than a 
lack of statistical significance for the association between OSA and stage 2 
hypertension. Balancing these limitations, this study has several strengths that 
lend confidence to our findings: it was a prospective study, which lends support 
to the evidence of a causal role of OSA in hypertension development; our 
subjects were from the general population, thus minimizing selection bias; the 
sample size was large and included a similar proportion of men and women and 
the follow-up period was prolonged (7.5 ± 0.8 years).  
Conclusions 
In summary, our results suggest an association between OSA patients 
and the risk of developing stage 2 hypertension in men. Increasing age was a 
significant factor explaining the presence of hypertension in men and women. 
Neither symptoms (EDS) nor nocturnal hypoxia were independently associated 
with the incidence of hypertension.
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TABLES 
Table 1. Baseline characteristics of normotensive patients at baseline included 
in the hypertension incidence analysis. 
Characteristics All 
(n = 1155) 
Men (M) 
(n = 505) 
Women (W) 
(n = 650) 
M/W  
p 
Age (years)  44.0 [37.0-52.0] 46.0 [39.0-54.0] 43.0 [37.0-50.3] < 0.001 
BMI (Kg/m2)  24.7 [22.6-27.0] 25.8 [23.9-27.7] 23.7 [21.5-26.0] < 0.001 
Neck 
circumference 
(cm)  
36.0 [33.0-39.5] 40.0 [38.0-42.0] 33.0 [32.0-35.0] < 0.001 
DM 56 (4.9) 25 (5.2) 31 (4.8) 0.749 
EDS a 209 (18.1) 105 (20.8) 104 (16.0) 0.036 
Habitual Snoring 
b
 
281 (26.8) 149 (35.6) 132 (21.0) < 0.001 
Smoking c  690 (59.7) 361 (71.5) 329 (50.6) < 0.001 
Alcohol use 503 (44.4) 321 (66.6) 182 (28.0) < 0.001 
Fitness level  561 (49.6)  263 (54.6) 298 (45.8) 0.004 
Hormonal status            
 Premenopausal 
 Perimenopausal 
 Postmenopausal 
 
436 (67.4) 
26 (4.0) 
185 (28.6) 
 
 
- 
 
436 (67.4) 
26 (4.0) 
185 (28.6) 
 
 
- 
RDI (events/h) 
RDI 0-2.9 
RDI 3-6.9 
RDI 7-13.9 
RDI ≥ 14 
    RDI ≥ 30 
4.0 [2.0-8.0] 
366 (31.7) 
417 (36.1) 
240 (20.8) 
132 (11.4) 
18 (1.6) 
5.0 [2.0-11.0] 
130 (25.7) 
165 (32.7) 
126 (25.0) 
84 (16.6) 
10 (2.0) 
3.0 [2.0-6.3] 
236 (36.3) 
252 (38.8) 
114 (17.5) 
48 (7.4) 
8 (1.2) 
< 0.001 
< 0.001 
0.032 
0.002 
< 0.001 
0.308 
CT90 0.0 [0.0-2.0] 
5.7 ± 17.7 d 
1.0 [0.0-5.0] 
10.5 ± 24.5 d 
0.0 [0.0-1.0] 
1.8 ± 7.0 d 
< 0.001 
ODI  4.0 [2.0-9.0] 5.0 [2.0-10.0] 4.0 [2.0-8.0] < 0.001 
SBP (mm Hg) 119.0 [110.0-
126.0] 
122.0 [116.0-
130.0] 
114.0 [107.0-
124.0] 
< 0.001 
DBP (mm Hg) 76.0 [70.0-80.0] 79.0 [73.0-80.5] 73.0 [68.0-80.0] < 0.001 
 
Data are presented as median [25th-75th percentiles] or number of patients (%) unless otherwise 
stated.  
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a EDS was defined as sleepiness for at least 3 or more days a week during the past 3 months in 
one or more of the following: after waking, during free time (leisure time), at work or driving, or 
during daytime in general according to the Basic Nordic Sleep Questionnaire.26 
b habitual snoring was defined as snoring more than five days per week. 
c current and former included. 
d mean ± standard deviation. 
Abbreviations: BMI: body-mass index; DM: diabetes mellitus; EDS: excessive daytime 
sleepiness; RDI: respiratory disturbance index; CT90: cumulative time percentage with SaO2 
<90%; ODI: oxygen desaturation index; SBP: systolic blood pressure; DBP: diastolic blood 
pressure.
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Table 2. Follow-up characteristics of normotensive patients at baseline. 
Characteristics All 
(n = 1155) 
Men (M) 
(n = 505) 
Women (W) 
(n = 650) 
M/W  
p 
Time of follow up 
(years) 
7.4 
 [6.9-8.0] 
8.2 
[7.6-8.7] 
7.1 
[6.8-7.4] 
< 0.001 
Age (years)                51.9 
[45.0-59.7] 
54.0 
[47.0-62.0] 
50.0  
[43.7-57.7] 
< 0.001 
BMI (kg/m2)                 25.7 
[23.4-28.2] 
27.1 
[25.1-29.2] 
24.3 
[22.3-26.8] 
< 0.001 
Change in weight (kg) 2.0 
[1.0-3.0] 
2.1 ± 4.0 a 
2.0 
[0.0-5.0] 
2.6 ± 5.0 a 
2.0 
[1.0-3.0] 
1.7 ± 2.9 a 
< 0.001 
SBP (mm Hg)  126.7 
[120.0-138.3] 
130.0 
[120.0-140.0] 
123.3 
[116.7-133.3] 
< 0.001 
DBP (mm Hg)  80.0 
[73.3-86.7] 
80.0 
[76.7-90.0] 
80.0 
[70.0-83.3] 
< 0.001 
Hypertension follow-up 
 No hypertension 
 Stage 1 hypertension 
 Stage 2 hypertension 
 
770 (66.7) 
295 (25.5) 
90 (7.8) 
 
289 (57.2) 
147 (29.1) 
69 (13.7) 
 
481 (74.0) 
148 (22.8) 
21 (3.2) 
 
< 0.001 
0.014 
< 0.001 
 
Data are presented as median [25th-75th percentiles] or number of patients (%) unless otherwise 
stated.  
a  mean ± standard deviation. 
Abbreviations: BMI: body-mass index; SBP: systolic blood pressure; DBP: diastolic blood 
pressure.  
Change in weight was defined as the difference between follow-up and baseline weight. 
Hypertension was defined as SBP ≥ 140 mmHg and/or DBP ≥ 90 mmHg or current treatment 
with antihypertensive medication.   
Stage 1 hypertension included all subjects with SBP 140-159 mmHg and/or DBP 90-99 mmHg. 
Stage 2 hypertension included subjects with SBP ≥ 160 mmHg and/or DBP ≥ 100 mmHg or 
those currently treated with antihypertensive medication. 
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Table 3. Odds ratios (OR) of the incidence of stage 2 hypertension according to 
the RDI. 
 
 
 
 
 
 
 
 
 
 
a adjusted for sex, age, BMI and neck circumference  
Abbreviations: RDI: respiratory disturbance index. 
RDI 
by subgroups   
Hypertension 
frequency  
n (%) 
Crude OR 
(95% CI) 
Adjusted OR a 
(95% CI) 
0-2.9 
(n = 366) 
14 
(3.8) 
1 1 
3-6.9 
(n = 417) 
25 
(6.0) 
1.60 
(0.82-3.13) 
1.22 
(0.61-2.44) 
7-13.9 
(n = 240) 
26 
(10.8) 
3.06 
(1.56-5.98) 
1.69 
(0.83-3.45) 
≥ 14 
(n = 132) 
25 
(18.9) 
5.87 
(2.95-11.70) 
2.51 
(1.18-5.33) 
n = 1155 n = 90   
 P trend < 0.001 0.017 
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Table 4. Adjusted odds ratios (OR) for the incidence of stage 2 hypertension 
according to the RDI and stratified by sex. 
 
a adjusted for age, BMI and neck circumference.  
Abbreviations: RDI: respiratory disturbance index. 
 
Men 
 
Women 
RDI 
by subgroups  
Hypertension 
frequency  
n (%) 
Adjusted 
ORa  
(95% CI) 
RDI 
by 
subgroups   
Hypertension 
frequency  
n (%) 
Adjusted OR 
a
  
(95% CI) 
0-2.9 
(n = 130) 
11 
(8.5) 
1 0-2.9 
(n = 236) 
3 
(1.3) 
1 
3-6.9 
(n = 165) 
21 
(12.7) 
1.42 
(0.65-3.10) 
3-6.9 
(n = 252) 
4 
(1.6) 
0.73 
(0.15-3.47) 
7-13.9 
(n = 126) 
18 
(14.3) 
1.53 
(0.67-3.47) 
7-13.9 
(n = 114) 
8 
(7.0) 
1.99 
(0.46-8.61) 
≥ 14 
(n = 84) 
19 
(22.6) 
2.54 
(1.09-5.95) 
≥ 14 
(n = 48) 
6 
(12.5) 
2.14 
(0.40-11.36) 
n = 505 n = 69  n = 650 n = 21  
 
P trend 0.032  P trend 0.371 
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Table 5. Risk subgroups for Stage 2 hypertension incidence obtained by the 
recursive partitioning method. 
Node Risk subgroup Stage 2 hypertension 
incidence  
OR  
(95% CI) 
p 
N % 
1 Women > 56 years and neck 
diameter > 35.3 cm 
7/25 28.0% 33.70  
(10.28-110.50) 
< 0.001 
2 Men and RDI ≥ 14/h 19/84 22.6% 25.33 
 (9.76-65.73) 
< 0.001 
3 Men and RDI < 14/h and > 40 
years 
41/297 13.8% 13.88  
(5.82-33.12) 
< 0.001 
4 Women ≤ 56 years and obese a 3/33 9.1% 8.67  
(2.07-36.36) 
0.003 
5 Women > 56 years and neck 
diameter < 35.3 cm 
5/66 7.6% 7.10  
(2.11-23.97) 
0.002 
6 Men and RDI < 14 and ≤ 40 
years 
9/124 7.3% 6.78  
(2.37-19.43) 
< 0.001 
7 Women ≤ 56 years and non-
obese a 
6/526 1.1% 1  
 
Abbreviations: N: number of patients; RDI: respiratory disturbance index. 
a Obesity was defined as BMI ≥ 30 Kg/m2. 
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Online supplements are not copyedited prior to posting and the author(s) take full responsibility for the accuracy of all data.  
e-Table 1. Predictive factors for the incidence of stage 2 hypertension, according to univariate and multivariate analyses. 
Variables Univariate analysis  Multivariate analysis  
n=1155 B Standard 
error 
OR (95% CI) p B Standard 
error 
OR (95% CI) p 
Sex (men) 1.556 0.257 4.74 (2.87-7.84) <0.001 1.618 0.413 5.04 (2.25-11.33) <0.001 
Age (years) 0.054 0.011 1.06 (1.03-1.08) <0.001 0.034 0.012 1.03 (1.01-1.06) 0.005 
BMI (kg/m2) 0.181 0.030 1.20 (1.13-1.27) <0.001 0.148 0.040 1.16 (1.07-1.25) <0.001 
Weight changea 
(kg) 
0.018 0.027 1.02 (0.97-1.07) 0.507     
Neck 
circumference 
(cm) 
0.167 0.027 1.18 (1.12-1.25) <0.001 -0.051 0.050 0.95 (0.86-1.05) 0.311 
DM 0.388 0.447 1.47 (0.61-3.54) 0.386     
EDSb 0.849 0.240 2.34 (1.46-3.74) <0.001     
Smokingc -0.088 0.222 0.92 (0.59-1.42) 0.693     
Alcohol 0.518 0.225 1.68 (1.08-2.61) 0.021     
Fitness activity 
(no) 
-0.044 0.223 0.96 (0.62-1.48) 0.844     
Postmenopause 2.029 0.524 7.61 (2.72-21.25) <0.001     
RDI 0-2.9    <0.001    0.064 
RDI 3-6.9 0.472 0.342 1.60 (0.82-3.13) 0.167 0.197 0.354 1.22 (0.61-2.44) 0.578 
RDI 7-13.9 1.117 0.343 3.06 (1.56-5.98) 0.001 0.527 0.363 1.69 (0.83-3.45) 0.147 
RDI ≥ 14 1.771 0.352 5.87 (2.95-11.70) <0.001 0.920 0.384 2.51 (1.18-5.33) 0.017 
CT90 0.013 0.004 1.01 (1.00-1.02) 0.005     
ODI 0.040 0.010 1.04 (1.02-1.06) <0.001     
 
a Change in weight was defined as the difference between follow-up and baseline weight. 
b EDS was defined as sleepiness for at least 3 or more days a week during the past 3 months in one or more of the following: after 
waking, during free time (leisure time), at work or driving, or during daytime in general according to the Basic Nordic Sleep 
Questionnaire.26 
c current and former included. 
Abbreviations: BMI: body-mass index; DM: diabetes mellitus; EDS: excessive daytime sleepiness; RDI: respiratory disturbance index; 
CT90: cumulative time percentage with SaO2 <90%; ODI: oxygen desaturation index; OR: odds ratio. 
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